By the Top Tier Newswire AI Desk · September 29, 2026 at 2:41 PM ET · reviewed against 21 wire stories
UNIQURE N V (QURE) is down -35.39% in the latest session. Our newswire has captured 21 stories on QURE across 14 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why QURE stock is down today
QURE stock is down 35.39% to $25.27 in today's session. The sharp decline follows the release of updated four-year data from uniQure's Phase I/II AMT-130 study in Huntington's disease. Analysts and investors are reacting to what they describe as mixed results, particularly concerning the durability of the gene therapy's effects. The stock has been under pressure since early in the session, with volume already reaching 20.4 million shares, 11.9 times the 3-month average.
What Happened
The updated AMT-130 trial data showed that the drug candidate failed to meet expectations for long-term efficacy, raising concerns about its path to regulatory approval. H.C. Wainwright analysts noted that the results complicate the case for the therapy's durability, a key factor for commercial viability. The stock opened at $39.22 but quickly dropped to a session low of $7.80 before stabilizing at $25.27. The Fly and InvestorsHub reported the stock falling as much as 38.4% and 64% at different points during the session. ClearPoint Neuro also saw a 24% drop after being affected by the same trial update.
The CEO and Chief Medical Officer of uniQure sold shares in the past month, with insider filings showing no buys and three sales totaling $3.3 million. A securities investigation was also announced by Kehoe Law Firm, adding to investor unease.
What The Data Shows
The stock has fallen 44.1% over the last eight sessions, from $44.00 to $24.59. The intraday session has seen a dramatic move from the open to the low, with unusual options activity showing a put premium of $215,000. The stock printed two fresh 52-week highs and two 52-week lows on September 29. The 30-day average sentiment score has deteriorated from 44 to 38 over the last seven days, reflecting growing pessimism.
What To Watch
The company is scheduled to release additional data in the coming months, and coverage breadth will be a key metric to monitor as the stock continues to face scrutiny.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
QURE · today's session (5-min) · -36.56% vs prior close · updated 6:55 PM ETAI sentiment, last 36h · averaged over 21 stories · 38/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoSeeking AlphaBULLISH 63Product/PR
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow
2026-09-29. The following slide deck was published by uniQure N.V.
6h agoThe FlyBEARISH 42General
uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright
QURE Investor Alert: Securities investigation on behalf of uniQure investors who suffered financial losses. ...
9h agoThe FlyBEARISH 34General
uniQure falls -36.4%
9h agoInvestorsHubBEARISH 22Earnings
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update
uniQure shares fall 64% after 48-month AMT-130 Huntington
9h agoInvestorsHubBEARISH 28Earnings
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
ClearPoint Neuro shares fall 24% after partner uniQure reports updated AMT-130 Huntington
9h agoBarron'sBEARISH 32Product/PR
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 48%
UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington’s disease falls short in a recent study.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →